Revive Therapeutics (CSE: RVV) this morning had a major announcement, in that it has entered into a sponsored research agreement with the University of California, San Francisco. The arrangement will see Bucillamine explored as a potential treatment for severe COVID-19.
The research conducted on Bucillamine is to be conducted in the lab of Dr John Fahy, a notable name as the lab is responsible for the report entitled, “Binding of SARS-CoV-2 spike protein to ACE2 is disabled by thiol-based drugs; evidence from in vitro SARS-CoV-2 infection studies.” The report serves as the basis for which Bucillamine was initially studied as a potential treatment for COVID-19.
Revive is currently undergoing a phase 3 study examining the use of Bucillamine in the treatment of mild-moderate COVID-19. The news today effectively expands ongoing research to include severe instances as well, although initial studies into the application for severe cases is currently pre-clinical.
“We are excited to expand the use of Bucillamine as a potential treatment for severe COVID-19 with our research agreement with UCSF and Dr. Fahy as Principal Investigator. Revive is focused on proving Bucillamine’s clinical utility for all forms of COVID-19. Evaluating Bucillamine for severe COVID-19 along with our dedication in completing our ongoing Phase 3 clinical study for mild-to-moderate COVID-19, which has grown from 14 clinical sites to now 26 participating sites in 10 U.S. states, will position Bucillamine as a potential oral treatment option for mild-moderate to severe COVID-19.”Michael Frank, CEO of Revive Therapeutics
Dr Fahy is a Professor of Medicine in the Division of Pulmonary and Critical Care Medicine and the Department of Medicine at the University of California, San Francisco. He also serves as a director of the severe asthma clinic at UCSF, along with the Airway Clinical Research Center.
Revive Therapeutics last traded at $0.48 on the CSE.
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.